FDA approves two devices for treatment of OAB
The FDA has granted approval to two devices indicated for the treatment of overactive bladder.
The FDA has granted approval to two devices indicated for the treatment of overactive bladder.
Uroplasty, Inc.’s Urgent PC Neuromodulation System is a non-surgical nerve stimulation device designed for office-based treatment of overactive bladder symptoms. The minimally invasive device uses targeted neurostimulation to disrupt the signals that trigger urinary urgency and frequency.
Medtronic Inc.’s InterStim II system has gained FDA approval for the treatment of intractable cases of overactive bladder and urinary retention. The InterStim II adds a new implantable neurostimulator, improved patient programmer, and upgraded software for the clinician programmer. It is a smaller, lighter version of the original InterStim device, which received FDA approval in 1997.
